Argenx's Vygart launch finds quick neurologist support over AstraZeneca's...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 17, 2022 at 11:22: PM
via Argenx nabbed an FDA approval for its rare disease drug Vyvgart just before Christmas and is wasting no time launching the generalized myasthenia gravis (gMG) med and setting it up to compete with AstraZeneca's Soliris.

article source
 

<



Similar threads

cafead
Navigating the AI &#039;hype cycle&#039;: Bayer, Daiichi Sankyo and argenx leaders on implementing AI in biopharma marketing
Replies
0
Views
8
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
J&amp;J unwraps pivotal data on $6.5B autoimmune asset as it prepares to crash argenx and UCB&#039;s party
Replies
0
Views
39
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
On blockbuster path, Argenx&#039;s red-hot Vyvgart comes up short in thrombocytopenia trial
Replies
0
Views
93
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Argenx&#039;s Vyvgart gains commercial momentum in gMG as company plots expansion into new uses
Replies
0
Views
263
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Vyvgart shines in CIDP study, teeing up another potential nod for Argenx&#039;s pipeline in...
Replies
0
Views
272
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote